Company profile
CARIBOU BIOSCIENCES, INC.
NASDAQ:CRBUBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VISPACABTAGENE REGEDLEUCEL | phase1 | — | 2 | unknown, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05722418 | phase1 | recruiting | 2023-02-06 | 2027-12-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma |
| NCT04637763 | phase1 | unknown | 2021-05-26 | 2025-08-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) |
| NCT06752876 | phase1 | withdrawn | 2027-12-01 | 2029-04-01 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) |
| NCT06128044 | phase1 | terminated | 2024-02-08 | 2025-05-30 | Caribou Biosciences, Inc. | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
FDA applications (0)
No records yet.